LaserAway's 229th Clinic: A Great Company, A Pricey Sale

On August 28, 2026, LaserAway opened its 229th clinic in University Park, Florida. The announcement reads like a routine expansion milestone. It's not. The same month, Reuters reported that the Los Angeles-based chain is exploring a sale that could value the business at more than $2 billion.

And here's what you need to know first: LaserAway is not a public company. You can't buy it. But the way this private company is being priced — and what its sale would signal about the med-spa industry — is worth your attention if you invest in healthcare, consumer services, or any of the few publicly traded players in this space.

The growth machine is real

The numbers behind LaserAway's expansion are hard to dismiss. When private equity firm Ares Management made a significant minority investment in 2021, the company operated 74 clinics. As of this week, it operates 229 across 36 states. That is nearly tripling the footprint in five years.

What separates this from typical PE-fueled growth is the closure record. LaserAway claims zero clinic closures in its 20-year history. In the med-spa business, where operators open and shutter locations with the regularity of fast-food rollups, that is unusual. It matters because closures destroy the very thing buyers pay for: recurring revenue. Laser hair removal treatments require multiple sessions over months. Botox patients return every three to four months. A shuttered location means lost treatment pipelines, not just lost rent.

The company's revenue mix has also evolved beyond its original identity. While LaserAway started as a laser hair removal brand, roughly half of its revenue now comes from non-laser services — injectables, skin treatments, and body contouring. That shift is not cosmetic. Injectable revenue is what med-spa buyers underwrite. Botox and fillers create repeat patients on predictable schedules, producing a revenue pattern closer to a subscription than a one-time purchase.

What $2 billion buys

Here is where the investment question sharpens. LaserAway reportedly generates approximately $150 million in annual EBITDA. A sale above $2 billion would imply an EBITDA multiple of roughly 13x.

For context, med-spa M&A valuations in 2026 typically run from 3x to 10x EBITDA depending on scale and quality. Even premium scale platforms — those with 15+ locations, MD-supervised compliance, diversified service mixes, and modern operating systems — command 8x to 10x EBITDA at the high end. A 13x multiple puts LaserAway's asking price well above the current market ceiling for aesthetic-service businesses.

The company has reasons to ask for more. Consumer Edge transaction data shows that among shoppers aged 25 to 34, LaserAway is gaining beauty-services spend share faster than any brand the firm tracks. Younger consumers are shifting toward specialized, brand-led formats — which is exactly what LaserAway has built. The company has also diversified beyond its original laser-hair-removal dependency and operates entirely company-owned locations, avoiding the quality control problems that plague franchise models.

But a higher multiple still needs to clear a basic test: is the growth durable enough to justify paying above what buyers are actually writing checks for? In this industry, the answer depends on same-store growth, customer retention, and whether the injectable pipeline keeps flowing as each new clinic matures. Those are the numbers a buyer's diligence team will press hardest on.

The broader consolidation

LaserAway sits inside a much larger trend. Private equity firms currently own roughly 3% of U.S. med spas, but that number is growing fast. The industry is highly fragmented — thousands of small operators across the country — and PE firms see a clear path to consolidation. Recent activity illustrates the pattern:

• General Atlantic completed its take-private of European Wax Center in 2026
• Stride Consumer Partners invested in neuromodulator-focused chain Peachy
• Sixth Street and Leonard Green & Partners back Milan Laser Hair Removal
• KKR has an investment in SkinSpirit
• Skytale Group has executed over 100 med-spa tuck-in acquisitions since 2022

That growth reflects a broader expansion: the global med-spa market is expected to grow from roughly $23 billion in 2026 to between $47 and $59 billion by 2031-2033, depending on the analyst. The underlying economics are straightforward: cash-pay revenue, repeat treatment demand, and a consumer trend that makes aesthetic treatments more mainstream and less taboo with each passing year.

What to watch

For investors who can't buy LaserAway directly, the company's sale process is still relevant. Here's what would change your view of this sector:

If the sale closes above $2.5 billion, it would establish a new multiple ceiling for aesthetic-service platforms and likely trigger a bidding wave across the fragmented med-spa market. Publicly traded players like SkinHealth Systems (NASDAQ: SKIN, formerly The Beauty Health Company, maker of the Hydrafacial brand) could re-rate upward. SKIN currently trades at a market cap of roughly $89 million — a steep contrast to the valuations being discussed for larger service platforms.

If the sale stalls or resets below $2 billion, it would confirm that the 8x–10x EBITDA ceiling is holding, and that even LaserAway's growth record and consumer traction can't push buyers above the line. That would be a signal that the med-spa consolidation wave, while real, is pricing discipline.

The 229th clinic in Florida is a data point in a larger story. The machine works — 74 to 229 clinics in five years, zero closures, and a revenue mix that now leans heavily on high-retention injectable services. But a $2 billion-plus sale price asks a lot of the market to believe that growth will keep accelerating, that margins won't compress under debt or integration costs, and that younger consumers will keep choosing branded chains over local practitioners. The clinic opening proves the first part. The sale process will test the rest.